EQS-Ad-hoc: aap Implantate AG / Key word(s): Capital Increase/Financing The Management Board of aap Implantate AG ("aap" or the "Company") announces that, following completion of the private placement as part of the capital increase with subscription rights, the capital measure has been fully subscribed. The Management Board of the Company participated in the capital measure to the extent of EUR 0.4 million. On 15 March 2023 the Management Board of aap resolved, with the approval of the Supervisory Board of the same day, to implement the capital increase against cash contributions out of the authorized capital 2022/I with subscription and oversubscription rights of the Company's shareholders resolved by the Management Board and Supervisory Board on 21 February 2023 in full. As part of the capital increase, 2,383,692 new no-par value bearer shares in aap with a pro rata amount of the share capital of EUR 1.00 each and with dividend rights from 1 January 2022 (“New Shares”) will thus be issued. All of the shares offered as part of the subscription offer were thus subscribed by shareholders or placed with investors by way of private placement. The capital increase with subscription rights raises aap's share capital by EUR 2,383,692.00 from the current EUR 6,571,261.00 to EUR 8,954,953.00. The New Shares were issued at a subscription price of EUR 1.40. Consequently, the capital measure results in gross issue proceeds of EUR 3.3 million, of which the Company will receive net inflows of approximately EUR 3.2 million in the short term after deduction of consulting fees and other costs. The issue proceeds from the transaction are to be used to strengthen aap's liquidity base. ------------------------------------------------------- aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -
About aap Implantate AG
Forward-looking statement
15-March-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | aap Implantate AG |
Lorenzweg 5 | |
12099 Berlin | |
Germany | |
Phone: | +49 (0) 30 75 01 90 |
Fax: | +49 (0) 30 75 01 91 11 |
E-mail: | info@aap.de |
Internet: | www.aap.de |
ISIN: | DE000A3H2101 |
WKN: | A3H210 |
Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1583685 |
End of Announcement | EQS News Service |
|
1583685 15-March-2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.